Garcia-Tsao G et al. Double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension (PH). (Abstract LB-01),Garcia-Tsao G, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019;69:717-28.
Effectiviteit en immunogeniciteit van het R21/Matrix-M-vaccin: 2 jaar follow-up
feb 2023 | Parasitaire infecties